ArticleCancer management and research2026
Financial Toxicity Profiles and Associated Factors in Patients with Advanced Cancer Receiving Daytime Chemotherapy: A Latent Profile Analysis.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Financial toxicity (FT) may persist among patients with advanced cancer receiving daytime chemotherapy because of prolonged treatment, frequent hospital visits, and nonmedical expenses. However, heterogeneity in this outpatient setting remains insufficiently understood. Aim: To identify latent FT profiles among patients with advanced cancer receiving daytime chemotherapy and examine factors associated with profile membership. Methods: This cross-sectional study recruited 335 patients with advanced cancer receiving daytime chemotherapy in Southwest China from November 2025 to January 2026. Participants completed the COST-PROM scale, Hospital Anxiety and Depression Scale, and Family APGAR Index. Latent profile analysis identified FT profiles, and forced-entry multinomial logistic regression examined adjusted associations. Results: Three profiles were identified: High FT (32.5%, n=109), Moderate FT (31.7%, n=106), and Low FT (35.8%, n=120). Univariate comparisons showed significant differences across demographic, socioeconomic, clinical, and psychosocial characteristics. With High FT as the reference, a higher total HADS score, representing overall psychological distress, was associated with higher odds of Moderate FT membership (adjusted odds ratio (aOR) = 1.081, 95% CI: 1.042-1.121), whereas disease duration < 6 months versus > 1 year was associated with lower odds (aOR = 0.437, 95% CI: 0.203-0.937). For Low versus High FT membership, disease duration <6 months versus >1 year (aOR = 4.394, 95% CI: 1.749-11.041) and each one-point increase in Family APGAR score (aOR = 1.536, 95% CI: 1.235-1.910) were associated with higher adjusted odds. Conclusion: FT showed cross-sectional heterogeneity in this population. The observed associations may inform context-specific assessment and supportive-care planning, but profile selection and several regression estimates remain uncertain. External and longitudinal validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.